Viking Therapeutics Surges 36% on Obesity Drug Data — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Viking Therapeutics (VKTX) stock surged 36% after the company released positive obesity drug trial data, per Barron's.
- Competitors Eli Lilly and Novo Nordisk saw their stocks fall on the Viking news, per Investor's Business Daily.
- Viking (VKTX) slipped 1.86% in subsequent trading, paring some of its initial surge.
Why it matters: Viking's 36% surge alongside a selloff in Eli Lilly and Novo Nordisk shows investors are pricing in a credible new challenger to the incumbents' obesity-drug dominance. The 1.86% pullback in VKTX after the pop hints that the initial euphoria is already fading.
Ask SkimNews
